A recent study reveals that nearly 30% of research funded by the pharmaceutical industry remains unpublished, raising significant concerns about transparency and accountability in clinical trials. This statistic underscores a persistent issue within the industry, where unfavorable results often do not see the light of day, potentially skewing the overall understanding of drug efficacy and safety.
The implications of these findings are profound, particularly for regulatory professionals, quality assurance teams, and sourcing experts who rely on comprehensive data to inform their decisions. The lack of published research can hinder the ability to assess the true value of treatments and may impact regulatory approvals and market access strategies. As stakeholders in the pharmaceutical landscape, it is crucial to advocate for greater transparency and push for changes that ensure all research findings, positive or negative, are made publicly available.
Get started today with Solo access →
